Should We Tax Robots on the Factory Floor?

 

Have you heard of the concept of robot taxation? It’s an idea that pushes for more taxes on companies that use robots over human labor, and supporters have a fierce advocate in their corner: Bill Gates. But does it make sense in the modern world, one in the midst of the fourth industrial revolution and driven by data and automation? Dan Allford, President of ARC Specialties, a provider of welding automation technology, joined us today to give his perspective on robot taxation and why, after his experience in the field, he think it’s a poor idea.

“I can only assume that Gates’ perspective on this is that it would save jobs. But automation has been part of manufacturing and other industries for a long time. Robots are just the newest form,” Allford said. “Think back to when looms replaced weavers. There was a fear of technology, but this innovation is the reason you have a closet full of clothes.”

Allford argued that automation improves people’s lives, and that robots haven’t hurt peoples’ jobs but rather empowered them. “Decades ago, 50% of all people were employed on the farm; now it’s only 2%. The result is we have plentiful, affordable food—not that jobs have been replaced,” he said.

“Look, robots have yet to take any fun jobs; they take the worst jobs. Jobs in dirty environments, hot environments, or even radioactive environments. So, it’s important for me to speak out on behalf of robots and automation,” Allford added.

Allford remembers, years ago, writing a paper on how the personal computer would wipe out typists. In this case, automation has affected the workforce. But he draws the connection between the end of the typist and Gates’ push for this taxation; he’s been one of the main catalysts for innovation in computer automation and automation in general.

“The truth is that placing a tax on a resurging market like manufacturing won’t save jobs. It will actually lead to more offshoring,” Allford said.

For the latest news, videos, and podcasts in the AEC Industry, be sure to subscribe to our industry publication.

Follow us on social media for the latest updates in B2B!

Twitter – @AECMKSL
Facebook – facebook.com/marketscale
LinkedIn – linkedin.com/company/marketscale

Follow us on social media for the latest updates in B2B!

Image

Latest

Doable
Rethinking Leadership: Why “Doable” Might Be the Most Powerful Strategy in Education Today
April 3, 2026

At a time when educator burnout is rising and schools across the U.S. are facing ongoing teacher shortages, leaders are being forced to rethink what sustainable success actually looks like. Research shows that teacher attrition is closely tied to working conditions, job-related stress, and workload demands. As districts push for innovation, data-driven instruction, and…

Read More
Casey Brown
From Poverty to Pricing Power | Why Great Companies Undercharge
April 2, 2026

Casey Brown didn’t grow up thinking she would become an entrepreneur. She grew up in a blue-collar family where money was always tight — close enough to the edge that the fear of poverty shaped many of her early decisions. That fear led her into engineering, into corporate America, and eventually into a moment…

Read More
Nightingales Summit: Empowering the Next Generation of Nigerian Nurses
Nightingales Summit: Empowering the Next Generation of Nigerian Nurses
April 2, 2026

In this episode of Care Anywhere, host Lea Sims sits down with Nigerian nurse entrepreneur and advocate Obafemi Arowosegbe to discuss leadership, mentorship, and the future of nursing in Africa. While still a nursing student, Obafemi founded the Nightingale Summit, a growing conference designed to empower nursing students and early-career nurses with leadership skills,…

Read More
Oncology
From Denial to Access: Rethinking Oncology Care Through AI, Clinical Trials, and Patient-Centered Innovation
April 1, 2026

The rapid expansion of precision medicine, biologics, and targeted cancer therapies is transforming oncology—but it’s also overwhelming a system not built to keep pace. In the U.S., cancer drugs now account for some of the highest-cost treatments in healthcare, and with that has come a surge in prior authorization requirements and denials. Studies suggest physicians…

Read More